In This Section:
The high prevalence and increasing incidence of obesity and associated cardiovascular risk emphasises the need to focus on obesity reduction in this high-risk population.
Metabolic syndrome (MetS) is the coexistence of obesity-related cardiovascular risk factors including hypertension, diabetes and dyslipidaemia. MetS is a precursor for atherosclerosis, including premature coronary artery disease, and cardiovascular mortality.
This educational hub has been supported by Boehringer Ingelheim. Boehringer Ingelheim has had no influence over the content. This educational hub is not intended for UK or IRELAND based physicians.
Other videos you might like
ECO 23: Impact of Obesity on Heart Failure Outcomes
Watch time: 7m 7s
What Matters to Patients: Metabolic Health Beyond Weight Loss
Watch time: 1m 40s (5 videos)
e-SPACE Cardio-Renal-Metabolic 2023
Watch time: 16h 19m 46s (19 videos)
Obesity Management Strategies in 2023
Watch time: 17m 7s
Bariatric Surgery Supported With Transvalvular Pumps: New Strategy for Morbidly Obese Patients to Get to Heart Transplantation
Evaluation of the Effect of Heart Failure Reversal Therapy on Anthropometric Obesity Parameters in Patients with Chronic Heart Failure: A Retrospective Analysis
Impacts of Adipocytokines and Obesity-associated Inflammatory Markers on Apolipoprotein A-1 and B in Patients on Statin Therapy
Excess Body Weight and Coronary Artery Disease - Associated Risks, the Obesity Paradox, and Implications for Cardiac Rehabilitation
The Million Hearts Initiative - Targeting Key Drivers of Cardiovascular Mortality from a Medical Specialty Society Perspective